Efficacy and safety of ADS-5102 (amantadine) extended-release capsules for treating levodopa-induced dyskinesia

Abstract

ABSTRACTIntroduction: Levodopa induced dyskinesia (LID) is a common motor complication affecting almost 95% of patients after 15 years of levodopa therapy. Dyskinesia in Parkinson`s disease (PD) can be functionally and socially disabling. Amantadine ER/ADS-5102/Gocovri™ is the first and only drug to get FDA approval in August 2017 for treatment of dyskinesias in patients with PD receiving levodopa with or without concomitant dopaminergic medication.Areas covered: This review summarizes the pharmacodynamics, safety and efficacy of Amantadine ER/ADS 5102 in the treatment of LID.Expert opinion: LID is a challenging problem in Parkinson’s disease. Although Amantadine IR is effective in treating LID, it is associated with a higher risk of CNS related side effects including sleep disturbances. Pharmacokinetic profile of Amantadine ER formulation consists of a slow rise and a sustained plasma level of approximately twice the level achieved by amantadine IR formulation. Once nighttime dosing of Amantadine ER provides a slow increase in plasma levels during the night and achieves the goal of maximal serum level during the most active hours of morning and mid-day making amantadine ER better tolerated and more efficacious as compared to IR formulations, in PD patients with troublesome dyskinesias.